|
Gene: ZNF469 |
Gene summary for ZNF469 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF469 | Gene ID | 84627 |
Gene name | zinc finger protein 469 | |
Gene Alias | BCS | |
Cytomap | 16q24.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | H3BS19 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84627 | ZNF469 | ATC11 | Human | Thyroid | ATC | 1.60e-07 | 8.53e-01 | 0.3386 |
84627 | ZNF469 | ATC12 | Human | Thyroid | ATC | 5.95e-07 | 2.48e-01 | 0.34 |
84627 | ZNF469 | ATC13 | Human | Thyroid | ATC | 4.70e-13 | 2.63e-01 | 0.34 |
84627 | ZNF469 | ATC3 | Human | Thyroid | ATC | 2.42e-14 | 9.16e-01 | 0.338 |
84627 | ZNF469 | ATC4 | Human | Thyroid | ATC | 3.55e-10 | 3.16e-01 | 0.34 |
84627 | ZNF469 | ATC5 | Human | Thyroid | ATC | 2.12e-13 | 2.82e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF469 | SNV | Missense_Mutation | novel | c.7987N>A | p.Gln2663Lys | p.Q2663K | Q96JG9 | protein_coding | tolerated(0.13) | possibly_damaging(0.804) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF469 | SNV | Missense_Mutation | novel | c.8948C>A | p.Ser2983Tyr | p.S2983Y | Q96JG9 | protein_coding | deleterious(0) | possibly_damaging(0.57) | TCGA-EY-A1GD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF469 | SNV | Missense_Mutation | rs187075195 | c.11483N>A | p.Arg3828His | p.R3828H | Q96JG9 | protein_coding | deleterious(0.04) | probably_damaging(0.993) | TCGA-EY-A1GF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF469 | SNV | Missense_Mutation | novel | c.6295C>A | p.Leu2099Ile | p.L2099I | Q96JG9 | protein_coding | tolerated(0.08) | probably_damaging(0.984) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF469 | SNV | Missense_Mutation | novel | c.2038N>A | p.Gly680Ser | p.G680S | Q96JG9 | protein_coding | tolerated(0.07) | possibly_damaging(0.891) | TCGA-EY-A548-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF469 | SNV | Missense_Mutation | novel | c.4913C>T | p.Pro1638Leu | p.P1638L | Q96JG9 | protein_coding | tolerated(0.49) | benign(0.007) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF469 | SNV | Missense_Mutation | rs555452824 | c.4442N>T | p.Pro1481Leu | p.P1481L | Q96JG9 | protein_coding | tolerated(0.06) | benign(0.347) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF469 | SNV | Missense_Mutation | novel | c.917T>C | p.Phe306Ser | p.F306S | Q96JG9 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ZNF469 | SNV | Missense_Mutation | novel | c.3670T>C | p.Cys1224Arg | p.C1224R | Q96JG9 | protein_coding | deleterious(0.02) | benign(0.02) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ZNF469 | SNV | Missense_Mutation | novel | c.6412C>A | p.Leu2138Met | p.L2138M | Q96JG9 | protein_coding | tolerated(0.06) | possibly_damaging(0.785) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |